Morgan Stanley analyst Michael Ulz maintained a Hold rating on Sarepta Therapeutics yesterday and set a price target of $20.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Hold rating due to a combination of factors related to Sarepta Therapeutics’ recent financial maneuvers and strategic focus. The company has successfully extended the maturity of a significant portion of its convertible senior notes from 2027 to 2030. This move enhances Sarepta’s financial flexibility, allowing it to continue funding its pipeline and focus on the sales of its key products, such as Elevidys and the PMO franchise.
While the extension of the debt maturity is a positive step, it also shifts the focus towards the company’s ability to execute its strategies effectively. Investors are now looking for more insights into the sales performance of Elevidys and the progress of Sarepta’s pipeline programs. These factors contribute to the Hold rating as the market awaits further clarity on the company’s execution and sales outcomes.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $20.50 price target.
SRPT’s price has also changed dramatically for the past six months – from $106.280 to $20.060, which is a -81.13% drop .